Building on the success of this novel approach, we used our well-established anti-CD26 antibody YS110 to develop CD26-targeted CAR-T-cell therapy for T-cell malignancies, demonstrating a greater anti-tumor effect of the third generation compared to the second generation of CAR. The gene discussed is DPP4; the disease is neoplasm.